Why the study?
SFRP5 is an anti-inflammatory adipokine that antagonizes WNT5A signalling, which is implicated in obesity, type 2 diabetes mellitus, and atherosclerosis, motivating a review of its pathogenic roles.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May identify SFRP5-WNT5A as a target in cardiometabolic inflammation; leaves open prospective human validation before clinical consideration.
Secreted frizzled-related protein 5 (SFRP5), an anti-inflammatory adipokine secreted by adipocytes, has been demonstrated to exert its anti-inflammatory effect via antagonizing the non-canonical wingless-type family member 5A (WNT5A) signalling pathways. The WNT5A protein, as a potent pro-inflammatory signalling molecule, is strongly involved in a variety of inflammatory disorders such as obesity, type 2 diabetes mellitus (T2DM) and atherosclerosis. In this review, we systematically outlined the current understanding on the roles of SFRP5 in the pathogenesis of three inflammatory diseases including obesity, T2DM and coronary heart disease (CHD). Our review might stimulate future research using SFRP5 as a promising novel therapeutic target for the treatment of obesity, T2DM and CHD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: